ALKS Alkermes plc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—
Margins
Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%
Returns
ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x
Cash quality & payout
Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.48B | $1.56B |
| Cost of revenue | $196.46M | $245.33M |
| Gross profit | $1.28B | $1.31B |
| R&D expense | $323.96M | $245.33M |
| SG&A expense | $701.52M | $645.24M |
| Operating income | $253.96M | $420.64M |
| Interest expense | $12.28M | $22.58M |
| Pretax income | $291.45M | $443.75M |
| Income tax | $49.79M | $71.61M |
| Net income | $241.66M | $367.07M |
| EBITDA | $281.12M | $449.17M |
| EPS (basic) | 1.47 | 2.22 |
| EPS (diluted) | 1.43 | 2.17 |
| Weighted avg. shares (diluted) | 168.74M | 169.20M |
| Balance sheet | ||
| Cash & equivalents | $388.57M | $291.15M |
| Short-term investments | $199.65M | $460.52M |
| Receivables | $334.02M | $384.53M |
| Inventory | $196.62M | $182.89M |
| Current assets | $1.93B | $1.42B |
| PP&E, net | $221.72M | $227.56M |
| Goodwill | $83.03M | $83.03M |
| Intangibles | $815,000 | $890,000 |
| Total assets | $2.49B | $2.06B |
| Current liabilities | $543.44M | $465.20M |
| Short-term debt | $0 | — |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $667.70M | $590.59M |
| Shareholders' equity | $1.82B | $1.46B |
| Net debt | -$388.57M | — |
| Shares outstanding | 165.61M | 162.18M |
| Cash flow statement | ||
| Operating cash flow | $520.75M | $439.12M |
| Capital expenditure | $40.42M | $33.48M |
| Free cash flow | $480.33M | $405.64M |
| Investing cash flow | $295.50M | -$111.31M |
| Financing cash flow | $12.38M | -$494.14M |
| Depreciation & amortization | $27.16M | $28.53M |
| Stock-based compensation | $98.72M | $96.64M |
| Share buybacks | — | $200.28M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.